Analyzing CannLabs (OTCMKTS:CANL) and Aclarion (NASDAQ:ACON)

Aclarion (NASDAQ:ACON) and CannLabs (OTCMKTS:CANL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Institutional and Insider Ownership

7.5% of Aclarion shares are held by institutional investors. 22.3% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Aclarion and CannLabs, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	0	0	1	0	3.00
CannLabs	0	0	0	0	N/A

Aclarion currently has a consensus target price of $1.50, suggesting a potential upside of 753.24%. Given Aclarion’s higher possible upside, equities analysts clearly believe Aclarion is more favorable than CannLabs.

Profitability

This table compares Aclarion and CannLabs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,967.15%	-910.84%	-218.13%
CannLabs	N/A	N/A	N/A

Valuation and Earnings

This table compares Aclarion and CannLabs”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$53,947.00	26.73	-$4.91 million	N/A	N/A
CannLabs	N/A	N/A	N/A	N/A	N/A

CannLabs has lower revenue, but higher earnings than Aclarion.

Risk and Volatility

Aclarion has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, CannLabs has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Summary

Aclarion beats CannLabs on 5 of the 9 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About CannLabs

CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. was incorporated in 2010 and is based in Denver, Colorado.